YK11 Oral Steroids Tablets 10mg 100pcs

Description

YK11 Myostatin Inhibitor SARM Research Peptide

Specification Sheet

• CAS Number: 1370003-76-1
• Molecular Formula: C25H34O6
• Molecular Weight: 430.54 g/mol
• Purity: >99.0% via HPLC-UV
• Appearance: Fine white to off-white crystalline powder

Pharmacodynamics

The biochemical activity of YK11 is defined by a dual-pathway mechanism that differentiates it from traditional SARMs. The primary mechanism involves the molecule enters the cell and agonizes the ligand-binding domain of the nuclear androgen receptor with a binding affinity (Ki) of approximately 0.5 nM. This defines the first semantic triple: [YK11 agonizes the nuclear androgen receptor]. Following this, this receptor engagement initiates a unique transcriptional program that upregulates the production of follistatin, a glycoprotein that acts as an antagonist to myostatin. This establishes the second triple: [Androgen receptor binding induces follistatin expression]. Furthermore, the resulting increase in systemic and localized follistatin levels binds to and neutralizes myostatin, thereby removing the negative regulatory brake on myogenic differentiation. This forms the third triple: [Increased follistatin inhibits myostatin activity]. In comparative studies, YK11 is distinguished from LGD-4033 Ligandrol; while both are selective, YK11 possesses a steroidal backbone that facilitates its unique induction of follistatin, a property not observed in non-steroidal SARM counterparts.

Product Profile

YK11 is a synthetic 19-norsteroidal derivative that functions as a high-affinity partial agonist of the androgen receptor while simultaneously acting as a potent gene-selective modulator of follistatin expression. [YK11 binds to the nuclear androgen receptor]. This signaling molecule serves as a primary research benchmark for investigating the bypass of genetic muscle limitations via the inhibition of myostatin activity.

Known Effects

• Acceleration of Myogenesis: Users in research models report significant increases in skeletal muscle cell differentiation and proliferation markers.
• Myostatin Suppression: Experimental findings suggest a marked reduction in genetic muscle growth inhibition through sustained follistatin elevation.
• Enhanced Muscle Hardness: Based on community feedback, effects include a distinct increase in myofibrillar density and visual vascularity.
• Bone Mineral Density Optimization: Multiple research groups note potential improvements in osteoblast activity and overall skeletal resilience.
• Fat Oxidation Signaling: Research models have observed shifts in metabolic substrate utilization, favoring lipid oxidation during caloric restriction.

Key Points:
YK11 represents a sophisticated research tool for investigating the targeted suppression of myostatin and the molecular pathways of androgen-mediated muscle hypertrophy.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.